untitled

Size: px
Start display at page:

Download "untitled"

Transcription

1

2

3 F F F F F

4

5

6

7 4. 436

8 5F A B 857 1No solitary fi brous tumor 1 02 ecchordosis physaliphora CT/MR pleomorphic xanthoastrocytoma 2 06 Lipomyelocele dural AVF 1 07 MRI IVR 2No H1N1 CT 10

9 12 X CT No MRI egfr No

10 No Von Recklinghausen disease diffuse ganglioneuromatosis CT 62 No Cavernous transformation F-FDG-PET 11 C-acetate-PET covered-stent BRTO 2

11 7 No D IVR 34 NBCA FPD-CT

12 5F No AIDS 1 39 Alexander MRI 1 43 CT 44 CT colonography undifferentiatedembryonalsarcoma 1 49 TAE 1 50 groove pancreatitis Type MR

13

14 12:06 13:00

15 9:00 9:49 01 Solitary fi brous tumor 02 ecchordosis physaliphora

16

17 1 30

18 MRI T2 202follow-up MRI T1WI T2WI STIR DWI MRI

19 GE RI

20

表1_表4

表1_表4 HN- 95 HN- 93 HN- 90 HN- 87 HN- 85 HN- 82 HN- 80 HN- 77 HN- 75 HN- 72 HN- 70 HN- 67 HN- 65 HN- 60 HN- 55 HN- 50 HN- 45 HN- 40 HN- 35 HN- 30 HN- 25 HN- 20 HN- 15 HN- 10 H02-80H H02-80L H02-70T H02-60H H05-60F

More information

1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR

More information

S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2

S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2 vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.

More information

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (

More information

02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…•

02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…• 8:55 9:00 19:00 9:32 29:32 10:04 AVF10:04 10:28 AVM10:28 11:00 111:00 11:24 211:24 11:48 12:00 13:10 13:10 13:20 13:20 14:20 14:20 14:30 14:30 14:46 14:46 15:10 115:10 15:42 215:42 16:14 16:14 9:00 9:24

More information

untitled

untitled 11 10 267 6 129 48.3 6 63 2 1 2JIS ME JIS T 1005JIS 1994 1 11 A 10 1999 5 3 13 ME 4 2 11 B B 1999 4 10 267 6 B 7 9 6 10 12 3 11 Excel MODE Excel STANDARDIZE STANDARDIZE(X,)X AVERAGE STDEVP Excel VAR 0.5

More information

PowerPoint Presentation

PowerPoint Presentation Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others

More information

- 16 M7.3 14 M6.5 - - - - - A-4 A-5 A-3 F-3 F-1 C-3 G-1,E-6 C-2 D-1 F-2 E-7 J-1 J-3 B-3 K-1 B-3 I-4 I-3 I-2 I-6 C-1 I-5 B-5 B-2 J-2 A-1 A-2 E-1 B-4 I-1 E-2 E-5 B-1,E-4 E-3 A-1 A-2 A-2 A-3 A-4 A-5 A-2

More information

PSCHG000.PS

PSCHG000.PS FA X % % IT M JQ LP CDLP CD LP CD N FM ton ight CD CD kg kg GW JM A T JM AT JM A T JC FA X a TEL CD TPP c c c c AIDS c c RS O VT1 VT2 VT1VT2 VT O O O RS RS RS c c c c c c c c FXa activated coagulation

More information

13 9 11 7 3 20

13 9 11 7 3 20 - 1 - 13 9 11 7 3 20 Point Point Point 1 2-1 - - 2 - - 3 - 1-4 - 2 3-5 - 1 2 3-6 - 1 2-7 - 3 4 5 6-8 - 1 2-9 - 1 2-10 - - 11 - - 12 - - 13 - 1 2-14 - 3 4 5 6 7-15 - 8-16 - - 17 - 1-18 - 2 1 2 3-19

More information

17 3/259/25 4/25 JR107 9/14 11/15 11/17 11/28 76 18 1/23 2/1026 3/20 WBC 7/14 9/6 9/26 9057 8

17 3/259/25 4/25 JR107 9/14 11/15 11/17 11/28 76 18 1/23 2/1026 3/20 WBC 7/14 9/6 9/26 9057 8 10 5 60 15 24 10 15 3/19 4/1 6/6 7/26 9/15 18 11/9 1 43 12/1 16 1/11 2038ATM 1/12 79 1/19 4/7 4/28 8/9 8/1329 9/1718 11/1 7 17 3/259/25 4/25 JR107 9/14 11/15 11/17 11/28 76 18 1/23 2/1026 3/20 WBC 7/14

More information

小児問題

小児問題 (glioma)(meningioma) (pituitary adenoma) (J-95 (J-4) angio (J-185) (J-173) Schwann MRI. ( ) PRL PRL GH V1 V2 V3 X X X Rinne test: 4-5cm test(+) Weber test: PRL Rathke s pouch() ( ) Willis 3 6 1. Tonic

More information

【日本放射線技術学会北海道部会メールマガジン 125号 2014/05/30 】

【日本放射線技術学会北海道部会メールマガジン 125号 2014/05/30 】 125 vol.125 2014/05/30 reader 42 Ambitious 2014 - make the next frontier, make the new future - [ ] 2014 10 9 ( ) 11 ( ) [ ] 003-0006 6 1 1-1 TEL 011-817-1010 [ ] ( ) ( ) [ ] ( ) [ ] 26 4 25 ( ) 6 1 (

More information

20●12頁●6-14▲放射線科▲.ppt

20●12頁●6-14▲放射線科▲.ppt No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%

More information

,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,

,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1, 1 1 1 2 1 3 1 4 2 5 5 6 6 1 6 2 7 3 7 4 7 5 7 7 8 8 10 1 10 2 10 3 10 12 1 12 2 12 3 12 4 13 5 14 14 1 14 1 2 3 4 5 1 2 3 4 16 5 16 6 16 7 17 6 17 18 19~23-19- 1 0.5 1 43.25 2.20 3.60 103.50 43.88 2.20

More information

肝臓病教室201207v2配布用.pptx

肝臓病教室201207v2配布用.pptx 24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

More information

8 8 0

8 8 0 ,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7

More information

1 5 6 2 3 7 8 4 5 9 10 6 7 11 12 8 1 2 3 4 5 6 7 1989 25.0% 19901999 6 2000 15.0% 9 13 1 2 3 4 5 50 2 5180 45.0% 81 35.0%, 5.0% + +, 5.0% +, 1, 5 +, 3 14 10 0% 20% 40% 60% 80% 100% n=20 3 5 2 n=20 55.0%

More information

IVR232.indb

IVR232.indb IVR Jpn J Intervent Radiol 23, 2008. 1 1 71 2 1 3D CTA DSA direct CCF 5 1CCF CCF 3D CTA 24 17/70 1999 1999 5 2004 12 92 83 76/92 1 1.3 1/76 93 71/76 1 1.3 1/76 370 CT 3 1 C3 2 C6 3 C5 1 1 1 546 2 1 2 3

More information

untitled

untitled 26 9 201491 PL PL PL 1 1 2 3 4 1 1 2 3 4 1,000 10 501003 7 5 6 2 10 1 1 10 2 2 1,000 1,000 50100 50100 50100 50 100 5 6 3 4 3 2 1 10 1100 11,000 1 5001,000 150 1,000 1,000 1,000 90 15001,000 15,000 15,000

More information

AD 2004/8/22 1. 30 90 mmhg 2. 3 100 refilling COPD etc. etc. PCPS IVR Helical CT DSA IVR DVT US/CT Scintigaraphy Ventilation / Perfusion VP scans High probability R DSA Gold standard MSCT

More information

() CT X X Ver.5 64 ( 3.0 % / 24,, 25 H23 1 Dr 24 24 2 1 25 RI RI ICU 24 25 B 4500 13000 AHA-PALS 5 PALS 24 25 24 25 24 ICU 24 25 24 1 VA VA 25 25 VA HD VA 20 150 () () 25 2 24 25 24 24 414 102 25

More information

untitled

untitled 1 Session 1 9 00 10 00 10 4 1 1-001 CBCT 1-002 CT 1-003 FOV 1-004 Area detector CT 1-005 CT Modulation Transfer Function 1 2 3 4 5 6 7 8 1-006 CT Noise power spectrum 1 2 3 4 5 67 8 Session 2 10 00 10

More information

11 第25回がん学会一般演題一覧(第3会場)

11 第25回がん学会一般演題一覧(第3会場) 1) 2) 1) 2) KTSND 2 200 KTSND KTSND 2014 4 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR 12 2015 4 CT 6 62 20XX 6 CTMRI 5 7 10 DIC methotrexatemtx /5-FU DIC score ALP

More information

1

1 1 6 7 8 9 10 11 12 13 14 15 21:00 22:00 23:00 24:00 18:00 19:00 20:00 16 1 3 ). ). ). 6 ). ). 9 10 12 ). ). 15 ). ). ). 20 ). ). ). 26 2 ). 2 39 3 ). 1. 2. 3. 4. 4 5. 6. ). 5 ). ( ) ( TWITraining

More information

A 01 2 015 10 11 12 G 011 2 0111 67

A 01 2 015 10 11 12 G 011 2 0111 67 66 A 01 2 015 10 11 12 G 011 2 0111 67 0119 0112 0113 68 0130 0128 0114 0113 0115 0116 0119 69 0111 0128 012 2 0121 1102 0122 0123 0124 70 0125 0126 0126 0111 0127 71 0128 0129 0230 013 0130 0130 011 012

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション 20 20 2003 15 1990 1990 2002 2002 12 12.....?. or 32 TN M0 1999 10 T1N0M0 93 10 dental CT dental CT MRI MRI : 55 TN0M0 1993 12 57 T3N0M0 938 1990 T1N0M0 1989 12 1990 99 99 4 T4 T4 T4 v.s.t2,3 T4 v.s.t2,3?

More information

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3)

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3) ...1...3...3 (1)...3 (2)...5 (3)...6 (4)...7...9 (1)...9 (2)...10 (3)...13 (4) 14 (5)...15...16 (1)...16 (2)...19...21 (1)...21 (2)...22 (3)...24...26...26 (1)...26 (2)...28 (3)...30 (4)...31 (5)...35

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

:,, : - 7 -

:,, : - 7 - 31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6

More information

4 15 C029 IVR angio-ct dynamic CT SSDE C030 C031 9:10~9:52 6. 核医学 1: 心大血管 肝胆膵 泌尿器 瀧 靖之 C032 3 SPECT MRI C033 FDG C034 99mTc-GSA C035 FDG-PET/CT C036 F

4 15 C029 IVR angio-ct dynamic CT SSDE C030 C031 9:10~9:52 6. 核医学 1: 心大血管 肝胆膵 泌尿器 瀧 靖之 C032 3 SPECT MRI C033 FDG C034 99mTc-GSA C035 FDG-PET/CT C036 F 4 月 15 日 ( 金 ) グラム4 15 一般演題 ( 電子ポスター ) 9:10~9:45 1. 循環器 1 吉村宣彦 C001 320 CT C002 CT DES TVF MACE C003 CT 3D maximum principal strain / C004 CT C005 CT 10:00~10:35 2. 循環器 2 木村文子 C006 Landiolol C007 Singe-source

More information

周辺動向調査(本文).PDF

周辺動向調査(本文).PDF X CT 14 1. 1 1.1 X 8 1.2 11 1.3 RI 12 1.4 MR MRI 13 1.5 13 1.6 14 2. XCT 15 2.1 XCT 15 2.2 XCT 18 2.3 19 2.4 CT 21 2.5 X CT 23 3. 24 3.1 25 3.2 29 4. 32 4.1 32 4.2 35 X CT 37 47 65 1 1. 2000 1 4,863 12

More information

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx 24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)

More information

ml ml ~ml : ml

ml ml ~ml : ml ml ml ~ml : ml , ) RI CT MRI( MRI (T2T1 MRI MR Mokri Mokri Mokri ICHD-II) Schievink post-lumbar puncture headache) 1938 Schaltenbrand spontaneous aliquorrhea( 1958 Shenkinlow cerebral spinal fluid pressure

More information

ÿþ

ÿþ YV-18 YV-19 YV-20 HALS Surgrx Enseal System 5 29 16:10 17:10 1-1 YP-1 YP-2 YP-3 YP-4 YP-5 YP-6 1 20 TS1 2 5 29 16:10 17:10 1-2 YP-7 YP-8 YP-9 YP-10 YP-11 YP-12 1 IPMN 1 4 3 2 Gemcitabine 5 29 16:10 17:10

More information

Digital Photo Professional Ver1.6(Windows)

Digital Photo Professional Ver1.6(Windows) Windows CT1-5193-000 CANON INC. 2005 J 1 2 3 4 s s s 1 1 s s s s s 1 1 a s s 1 s s 1 2 s a 1 s a 2 3 1 1 s a a 2 a 3 a s s 1 a a s a s s 1 s s 1 2 3 s 1 1 a 2 a 1 a s 2 3 1 1 s a 2 1 3 1 s a 2

More information

★プログラム並べかえ.indb

★プログラム並べかえ.indb 1 2 3 1 S180 S181 S182 S183 2 3 S184 S185 MRI S187 S188 S189 1 2 1 2 S 37 B flow imaging 1 1 1 2 1 1 S190 2 IVUS 1 2 3 4 5 1 2 S191 3 4 5 : MDCT MRI DSA S192 1 1 1 2 1 2 MR MRI FUS HIFU S194 S195 S196

More information

w NEWS NEWS Y

w NEWS NEWS Y No.472 FEB. 200315 w NEWS NEWS Y e r Y E t 1 1 y u i B 1 1 Y c fa g f o p mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr A 1 !0 1 1

More information

untitled

untitled 191018 1. 2. 3. 2 Rx =Prescription Drug NEC =New Chemical Entity GE =Generic Drug OTC =Over The Counter 3 04 5 23 35 510 23 6 R&D 7 8 2005 ( best in class ) MR power marketing HMG-CoA 12,963 6,223 Ca ++

More information

10mm -1-

10mm -1- PKD.45.6.45.3.46.8.45.6.55.9.54.3.56.4 H.3.3 4 H.7.3 15.62.6 10mm -1- -2- CT CT CT 90 CT MRA MRA MR MRI CT -3- Hunt & Kosnik 1974 Grade Grade Grade a Grade Grade Grade Grade 2922 78.7 % 8.6 % 4.4 % 8.3

More information

22肝胆膵_抄録_1_ indd

22肝胆膵_抄録_1_ indd 001 5 26 11:30 12:30 9-1 PO001-1 PO001-2 I II 2cm MRI PO001-3 PO001-4 PO001-5 PO001-6 5cm (Vp3/4,Vv2/3) PO001-7 1 PO001-8 B HCC C HCC B HCC PO001-9 002 5 26 11:30 12:30 9-1 PO002-1 HDAC PO002-2 Down Staging

More information

がん診療におけるFDG FDG-PET/CTの役割

がん診療におけるFDG FDG-PET/CTの役割 PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT

More information

全国循環器撮影研究会 HP講座No

全国循環器撮影研究会 HP講座No HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased

More information

<91E F D834F D5A90B32E696E6464>

<91E F D834F D5A90B32E696E6464> 日時 : 平成 27 年 2 月 28 日 ( 土 ) 午前 9 時 15 分 ~ 午後 5 時 20 分 会 場 : ブリーゼプラザ 7 階小ホール 530-0001 大阪市北区梅田 2-4-9 ブリーゼタワー TEL:06-6344-4888 FAX:06-6344-4666 世話人会 : 平成 27 年 2 月 28 日 ( 土 ) 午前 11 時 50 分 ~ 午後 12 時 50 分ブリーゼタワー

More information

電子ポスタープロ.indd

電子ポスタープロ.indd S 269 C001 Cavernous sinus dural arteriovenous fistulas with unusual posterior termination of the superficial middle cerebral vein via laterocavernous sinus: A pitfall of transvenous embolization C002

More information

Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L

More information

2005 8) Robbins and Cotran Pathologic Basis of Disease (7th ed.) Kumar V, Abbas AK, Fausto N (eds.), W.B. Saunders, ) Rubin s Pathology (4 th ed

2005 8) Robbins and Cotran Pathologic Basis of Disease (7th ed.) Kumar V, Abbas AK, Fausto N (eds.), W.B. Saunders, ) Rubin s Pathology (4 th ed 23344 mfukayama-tky@umin.ac.jp http://pathol.umin.ac.jp/ 19 50 2 / 19 50 3 / http://pathol/umin.ac.jp 1) Basic Pathology (7 th edition): Kumar V, Cotran RS, Robbins SL (eds.), W.B. Saunders, 2002 2) Essential

More information

2

2 1 2 3 1) 2) 3) 2 3 1 2 3 4 5 6 7 8 9 10 11 4 12 13 14 15 X 16 X 17 X CT 18 MRI 19 20 4 A. ENG T&T B. ABLB SISI ABR ASSRMLRSRL 5 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 6 1 2 3 4 7 1 POS( Problem

More information

1) Asa, S. L., et al.: Immunohistochemical localization of neuron-specific enolase in the human hypophysis and pituitary adenoma, Arch. Pathol. Lab. Med., 108: 40 `43, 1984. 2) Chi, B. H. and Kim, R. C.:

More information

83

83 Candida sppmssa Haemophilus influenzae consolidation consolidation consolidation consolidation consolidation consolidation knuckle sign Westermark sign Hampton s hump Borchardt enteropathy-associated

More information

10K1A NASA () SPACE ATLAS Freedom H2A NASA 1

10K1A NASA () SPACE ATLAS Freedom H2A NASA 1 10O1A 10 10 1 10K1A NASA () SPACE ATLAS 40 1957 1969 10 1986 1990 Freedom 20 000 H2A NASA 1 10K1A 100 10 21 40 1996 ( 200 () 2 10S1A 10 8 57 250 1 10S1A 20 200mmm 2 10S1B 18 18 1 10S1B 40 10 20 2 10S1C

More information

E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1-

E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1- E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1- LD LD LD -2- MBD Minimal Brain Dysfunction Syndrome -3- Minimal Brain Dysfunction Syndrome : --- WISC-WPPSIK-ABC --- CTMRIEEG --- 40 60-4- -5- MBD MBD MBD MBD

More information

第12回臨床画像大会

第12回臨床画像大会 2007 47 3130 146 12 2007 10 19 20 Landmarks for Imaging of Head Neck Cancer Hugh D. Curtin, MD Department of Radiology Massachusetts Eye and Ear Infirmary Head and neck carcinoma is almost always diagnosed

More information

NEDO

NEDO 10 MRI 1 1 595% 5 IOR 100% MRI MRI MRI MRI MRI MRI 11 MRI 3 2 1 MRI 1 1.5 0.000005 100 5 MRI MRI MRI MRI MRI MRI MRI MRI MRI (1) MRI MRI 0.3 3 MRI 1 / (2) MRI MRI (3)MRI MRI 3 (4)MRI MRI MRI (5)MRI 2006

More information

untitled

untitled 18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B

More information

Topic MRI Phased array coil SNR Saturation band T1T2 T1T2 Localizer( ) T2WI + T1WI ( ) - Option PROPELLER BLADE BLADE Blade (-) Blade (+) SPACE (sampling perfection with application optimized contrasts

More information

General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2)

General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2) General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2) (3) (4) (Standard Precautions ) (5) ( ) (6) (7) ( ) ( ) QOL(Quality of Life) ( ) (8) 1 2 (1) (2) (3) 4 24 (4) 3 ABC3 (common

More information

AOC AOC DICOM.1 AOC AOC.1.1 CD/DVD AOC 4

AOC AOC DICOM.1 AOC AOC.1.1 CD/DVD AOC 4 AOC AOC 1 1 1 DICOM.1 AOC AOC.1.1 CD/DVD AOC 4 .1.2.1.3.1.4 DICOM DICOM AOC AOCAOC Server AOC DICOMAOC AOC Scan AOC DICOM 5 DICOM Study Description DICOM DICOM CD CD/DVD AOC CD/DVD CD/DVD 2 DICOM.1.5 85..3

More information

FC p07

FC p07 GZ 1 2 L2 GE-R-KEG S1 2 I1 R (BSPT) thread 1 WE-R-KEG S3 I3 2 I2 1 RI-ED VSTIR-ED 1CA43 LEO-2 L - 24 O ISO 12151-2 - SWS W A C B mm mm mm mm mm 1CA43-6-4 6 M12x1,5-6 1/4-4 1.81 46-0.02-1 14 1.06 27 1CA43-8-4

More information

天草郡市医師会第139回(臨時)代議員会

天草郡市医師会第139回(臨時)代議員会 A 97 2(B A2) 4(A B3) 2 95 B 104 25(A B3) 16(B A2) 9 113 201 27 20 7 208 2 1 13 3 18 4 19 3 3 2 2 13 4 17 3 18 6 26 6 30 17 18 17 17 17 17 18 ( ) 18 ( ) 18 ( ) 18 ( ) 18 ( ) ( ) ( ) ( ) ( ) ( ) 18 ( ) (

More information

青森県2012-初校.indd

青森県2012-初校.indd http://www.kairyudo.co.jp/ 2012 AOMORI 2 3 9 16 1 2 3 2010 6 128.9 128.2 128.7 8 9 31.7 30.0 31.7 30.0 22.5 21.4 21.9 21.0 117.2 116.7 116.3 115.8 65.1 64.9 64.7 64.5 7 25.3 24.0 24.9 23.5 123.1 122.5

More information

Dokument:

Dokument: 13 13 13 13 13 13 13 13 13 13 13 13 13 13 08 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 08 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 08 13 13 13 13 13 13 13 13 13fa

More information

32 TEL: 0959-52-3000 FAX: 0959-52-4467 Email: nkh@orange.ocn.ne.jp URL: http://www.kamigoto-hospital.jp/ 1 73 MRI IT IVR PTCA 74 MC CT) NECMega-Ork 75 Web HTLV-IATL 2 ICU Holter MD-C T MRIX DSAFCR 3 4

More information

1958 1984 1985 1 1985 1987 1987 1992 2004 j - 1996 j 1996 12 j 1997 6 1997 j 1998 6 j 1998 6 j 1998 9 1998 2000 2-01 j 2000. 12 2000.7.24 2001 2001.12

1958 1984 1985 1 1985 1987 1987 1992 2004 j - 1996 j 1996 12 j 1997 6 1997 j 1998 6 j 1998 6 j 1998 9 1998 2000 2-01 j 2000. 12 2000.7.24 2001 2001.12 1958 1984 1985 1 1985 1987 1987 1992 2004 j - 1996 j 1996 12 j 1997 6 1997 j 1998 6 j 1998 6 j 1998 9 1998 2000 2-01 j 2000. 12 2000.7.24 2001 2001.12 2002.4 2002 2003.9 2003 2004 2005. 2006 2007.11 2008

More information

MISS Voice 4 MISt QOL (PPS) MISt MISt MISS Voice Theme #.1 Minimally Invasive Spine Stabilization: MISt 2005 MISt ADL QOL MISt MIS

MISS Voice 4 MISt QOL (PPS) MISt MISt   MISS Voice Theme #.1 Minimally Invasive Spine Stabilization: MISt 2005 MISt ADL QOL MISt MIS Vol.4 MISt (Minimally Invasive Spine Stabilization: MISt ) MISt MISS Voice 4 MISt QOL (PPS) MISt MISt http://mist.umin.jp MISS Voice Theme #.1 Minimally Invasive Spine Stabilization: MISt 2005 MISt ADL

More information

von Willebrand 1. 2 (i) (ii) 2. (i) 23G 25G (ii) (iii) 3 5 3. Table 2 + 4. 3 5 5. 1980 1. Kogenate, Bioclate, Helixate, Recombinate; 2. AHF-M, Hemofil

von Willebrand 1. 2 (i) (ii) 2. (i) 23G 25G (ii) (iii) 3 5 3. Table 2 + 4. 3 5 5. 1980 1. Kogenate, Bioclate, Helixate, Recombinate; 2. AHF-M, Hemofil Full Haemophilia Translation: (2000), Hemophilia 6, (Suppl.1), of Georgia 84-93 Hemophilia of Georgia 1 Treatment of Hemophilia Monograph Series, Number 14. World Federation of Hemophilia: 1998. Protocols

More information

Stage 28 4 28 7 !! 15 EMB POMRProblem Oriented Medical Record SOAPSubjectiveObjectiveAssessmentPlan 1 2 ID 3 ID SOAP 4 5 6 ~ ~~~~~~~~~~~~~ Stage Stage 2 1. X CT 2. 1 30 60 3. 5. 4

More information

日本歯科放射線学会

日本歯科放射線学会 191 22 10 1. PET RI 18F-fluolodexyglucose ( 18 FDG) CT (PET) 18FDG RI SUV T SUV SUV 18FDG 18FDG PET 11C-methionine Hela S3 thymidine (FCM) DNA FITC anti-bromodeoxyuridine-fitc (Glucosetransporter 1 : Glut

More information

レントゲン X線

レントゲン X線 PET ( TIAN Mei ) PET 100 PET PET PET PET PET Positron Emission Tomography (PET) PET Positron Emission Tomography CT PET FDG Glucose and 18 F-FDG 18 F-FDGFDG CH3OH O CH3OH O OH OH OH OH OH OH OH 18 F *FDG

More information

41-6_50回中国地方会Pr6N__HP掲載用.indd

41-6_50回中国地方会Pr6N__HP掲載用.indd 2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.

More information

ii

ii 2013555000000 1 ii iii iv v vi vii viii ix x xi xii xiii xiv xv xvi ii v vi vii xxiii 1 2 3 4 5 xxvi 6 1 1 1 2 3 5 6 7 8 10 12 13 2 15 17 18 19 20 21 22 23 15 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

More information

-2-

-2- Super Lizer HT-2200 m m W Super Lizer -1- -2- -3- -4- stellate ganglion block stellate ganglion -5- -6- -7- -8- IgA -9- " " -10- -11- 5 6 10 1-12- -1- -2- mv -3- -4- -5- -1- : -2- No.2576 P.25 1973-3-

More information

untitled

untitled 19 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15 19 19 1 17,676 20.0 2 20,970 24.1 3 4,967 23.2 104,10919 4 8,234 18.0 11,428 22.4 1 0 10,954244 17,107 18.7 136 4.8 12,653205 1,239 13.2 10,056686 27,305514

More information